Elisabeth de Darkó
Keine laufenden Positionen mehr
Karriereverlauf von Elisabeth de Darkó
Ehemalige bekannte Positionen von Elisabeth de Darkó
| Unternehmen | Position | Beginn | Ende |
|---|---|---|---|
| Yamanouchi Nordic | Technik-/Wissenschafts-/F&E-Leiter | - | - |
| General Counsel | - | - | |
Valderm ApS
 Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Vorstandsvorsitzender | 01.04.2006 | - |
Statistik
International
| Dänemark | 3 |
Operativ
| Chief Executive Officer | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| General Counsel | 1 |
Sektoral
| Health Technology | 2 |
Besetzte Positionen
Aktive
Inaktive
Börsennotierte Unternehmen
Private Unternehmen
Unternehmensverbindungen
| Private Unternehmen | 2 |
|---|---|
Valderm ApS
Valderm ApS Pharmaceuticals: MajorHealth Technology Valderm ApS is focused on the development of the second generation anthracycline valrubicin for innovative once daily topical treatment of hyper proliferative skin diseases e.g. psoriasis. Preclinical studies have confirmed the anti-proliferative effect of valrubicin and an attractive safety profile upon repeated topical applications has been documented. The company was founded in 2003 and is headquartered in Lyngby, Denmark. | Health Technology |
| Yamanouchi Nordic |
- Börse
- Insiders
- Elisabeth de Darkó
- Erfahrung
